Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
Noosa News23 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
General24 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News23 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
General22 hours agoPort’s lease a ‘mistake’ as major parties flag takeover